KB-1091

Ifinatamab

46629

Background of Ifinatamab

Ifinatamab deruxtecan (I-DXd; DS-7300) is a novel ADC that shows great promise as an anti-cancer agent. Comprised of an anti-B7-H3 antibody linked to the DNA topoisomerase I inhibitor, DXd, I-DXd has demonstrated impressive anti-tumor activity in preclinical cancer models that express B7-H3. Early clinical trials have also reported encouraging results, showing I-DXd to be effective in patients with advanced solid tumors who had undergone extensive prior treatment. The mechanism of ADCs relies on the compound's target-specific uptake, leading to cytotoxicity in tumors expressing the target antigen.

Specifications

Catalog Number	KB-1091
Antibody Name	Ifinatamab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	B7-H3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA\|FACS\|KD
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Wespiser M, Gille R, Pérol M. Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. Expert Opin Investig Drugs. 2025 Jun;34(6):463-471.